




RealRate

PHARMACEUTICAL 2021

CHINA PHARMA HOLDINGS INC.
Rank 121 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of CHINA PHARMA HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINA PHARMA HOLDINGS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 244% points. The greatest weakness of CHINA PHARMA HOLDINGS INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 189% points.

The company's Economic Capital Ratio, given in the ranking table, is -7.4%, being 347% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	5,322
Cost of Goods Sold	8,914
Intangible Assets	182
Liabilities, Current	11,404
Liabilities, Non-Current	0
Other Assets	50
Other Compr. Net Income	769
Other Expenses	2,331
Other Liabilities	1,710
Other Net Income	-288
Property and Equipment	15,564
Research and Development	378
Revenues	10,866
Selling, General and Administrative Expense	1,823

Output Variable	Value in 1000 USD
Assets	21,118
Liabilities	13,113
Expenses	13,445
Stockholders Equity	8,005
Net Income	-2,867
Comprehensive Net Income	-2,482
Economic Capital Ratio	-7.4%